This study, using single-cell sequencing and spatial multi-omics technologies, reveals ZNF683+ NK cells as 'gatekeepers' of chemotherapy efficacy, driving CD8+ T cell activation, thereby providing novel biomarkers and intervention targets for overcoming chemotherapy resistance in head and neck cancer.
Literature Overview
The article titled 'ZNF683+ NK cells govern chemotherapy sensitivity in advanced HPSCC via reshaping immune microenvironment,' published in Nature Communications, reviews and summarizes the immune mechanisms underlying resistance to the TPF chemotherapy regimen in advanced hypopharyngeal squamous cell carcinoma (HPSCC). By integrating longitudinal single-cell RNA sequencing, spatial multiplex immunohistochemistry, and functional validation, the study systematically characterizes the dynamic changes in the immune microenvironment before and after chemotherapy, identifying a critical role for ZNF683+ NK cells in determining chemotherapy sensitivity. This NK cell subset activates GZMK+CD8+ effector memory T cells in an MHC-I-dependent manner, thereby enhancing anti-tumor immune responses. The study further confirms that the baseline infiltration level of ZNF683+ NK cells prior to treatment can effectively predict response to TPF therapy, providing a theoretical basis for personalized treatment strategies. This work not only uncovers the central regulatory function of the NK–CD8+ T cell axis in HPSCC but also lays the foundation for developing novel immune interventions to overcome chemotherapy resistance.Background Knowledge
Hypopharyngeal squamous cell carcinoma (HPSCC) is the most aggressive subtype of head and neck squamous cell carcinoma, often diagnosed at an advanced stage due to its anatomical concealment and lack of early symptoms, resulting in a 5-year survival rate of only 25–35%. Currently, TPF (docetaxel, cisplatin, 5-FU) induction chemotherapy is the first-line treatment regimen for larynx preservation, but approximately 10–20% of patients exhibit primary resistance, missing the therapeutic window. Although genomic studies have revealed some resistance mechanisms, traditional bulk sequencing struggles to resolve the heterogeneity and dynamic changes of immune cells within the tumor microenvironment (TME). In recent years, single-cell transcriptomic sequencing (scRNA-seq) has provided high-resolution insights into the functions and interactions of immune cell subsets within the TME. Previous studies in other cancers have highlighted the roles of T cell subsets (e.g., exhausted T cells, memory T cells) in immunotherapy response, yet HPSCC exhibits distinct clinical behaviors and treatment responses, lacking systematic single-cell investigations into its chemotherapy resistance mechanisms. In particular, the functional heterogeneity of NK cells in HPSCC and their interaction mechanisms with T cells remain poorly understood. This study fills that gap by focusing on the regulatory role of NK cell subsets in chemotherapy response, integrating multi-omics data with functional experiments to reveal a novel 'coordinator' function of ZNF683+ NK cells in the immune microenvironment, providing key insights for developing predictive models and combination therapies based on immune microenvironment features.
Research Methods and Experiments
The study enrolled 12 HPSCC patients receiving two cycles of TPF chemotherapy as a discovery cohort, collecting paired tumor samples before and after treatment for single-cell RNA sequencing (scRNA-seq) and bulk RNA-seq analysis. An additional cohort of 41 patients was used for immunohistochemistry (mIHC) and flow cytometry validation. CD45+ immune cells were isolated via FACS, and the tumor-infiltrating immune landscape was systematically analyzed using UMAP clustering and marker gene identification. RNA velocity and pseudotime analysis were applied to investigate the developmental trajectories of NK cell subsets. Cell–cell interaction networks were predicted using CellChat, and the contact-dependent interaction mechanism between ZNF683+ NK cells and CD8+ T cells was validated through in vitro co-culture and MHC-I blocking experiments. A Znf683 conditional knockout mouse model was generated to assess its impact on MHC-I expression and T cell activation. In vivo functional validation was performed using the MEER mouse tumor model, with NK cell depletion via anti-NK1.1 antibody to evaluate effects on TPF efficacy.Key Conclusions and Perspectives
Research Significance and Prospects
This study innovatively extends the functional role of NK cell subsets beyond traditional cytotoxicity to that of 'coordinators' of the immune microenvironment, revealing the central role of ZNF683+ NK cells in chemotherapy-induced anti-tumor immunity. This finding provides new perspectives on how chemotherapy reshapes the immune microenvironment and identifies potential intervention targets for overcoming chemotherapy resistance in HPSCC. Future studies may further explore the upstream regulatory mechanisms of ZNF683 and its conservation across other cancer types.
Potential therapeutic strategies based on this NK–CD8+ axis include enhancing in vivo expansion or adoptive transfer of ZNF683+ NK cells; developing small molecules or antibodies targeting the MHC-I/CD8 interaction; or combining NK cell activators with chemotherapy to improve efficacy. Furthermore, surface markers of ZNF683+ NK cells (e.g., CX3CR1-KIT-) offer feasible clinical detection approaches, potentially enabling patient stratification and treatment decision support.
Conclusion
This study systematically characterizes the dynamic changes in the immune microenvironment of HPSCC patients before and after TPF chemotherapy, revealing ZNF683+ NK cells as key regulators of chemotherapy sensitivity. By integrating single-cell transcriptomics, spatial proteomics, and functional experiments, the study demonstrates that this NK cell subset drives the activation and expansion of GZMK+CD8+ effector memory T cells via MHC-I-dependent direct contact, forming a positive feedback loop in anti-tumor immunity. The pre-treatment infiltration level of ZNF683+ NK cells effectively predicts chemotherapy response, offering a potential clinical biomarker. This work not only deepens our understanding of non-cytotoxic NK cell functions but also provides new insights for overcoming chemotherapy resistance in head and neck cancer. Future combination therapies based on the NK–CD8+ axis are expected to improve survival outcomes for HPSCC patients and advance personalized immunochemotherapy. Additionally, the study establishes a single-cell atlas of chemotherapy-induced immune remodeling in HPSCC, serving as a valuable resource for subsequent mechanistic investigations and drug development.
